Quality of life (QOL) analysis from the phase II RIGHT choice study of first-line ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2-advanced breast cancer (ABC)

Abstract

Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid, SPAIN, OCT 20-24, 2023